|Other names: Lymphoedema, lymphatic edema, lymphatic obstruction, lymphatic insufficiency|
|Lower extremity lymphedema|
|Specialty||Vascular medicine, physical medicine and rehabilitation, plastic surgery|
|Symptoms||Swelling, discomfort, heaviness, joint stiffness, skin thickening|
|Complications||Infection, deep vein thrombosis, lymphangiosarcoma|
|Types||Stage 0 to 3|
|Causes||Cancer, parasitic infections, genetic disorders|
|Diagnostic method||Based on symptoms|
|Differential diagnosis||Lipodystrophy, venous insufficiency, heart failure, kidney problems, cirrhosis|
|Treatment||Compression therapy, good skin care, exercise, manual lymphatic drainage|
Lymphedema is localized swelling due to a compromised lymphatic system. Other symptoms may include discomfort, heaviness, joint stiffness, and skin thickening. Complications may include infection, deep vein thrombosis, and lymphangiosarcoma.
It most frequently occurs due to cancer and its treatment or parasitic infections (lymphatic filariasis), but may also be seen in a number of genetic disorders. Risk factors include obesity. The underlying mechanism involves a cycle of inflammation and fibrosis. Diagnosis is generally based on symptoms, after other potential causes are ruled out.
While there is no cure, treatment may improve outcomes. This commonly include compression therapy, good skin care, exercise, and manual lymphatic drainage (MLD), known together as combined decongestive therapy. Exercise may also be useful. Diuretics are not useful. Surgery is generally only used in those who are not improved with other measures.
Lymphedema affects approximately 200 million people worldwide. Women are more commonly affected than men. About 1 in 5 women who survive breast cancer and 40% of women with gynecologic cancer develop lymphedema. Genetic causes are much less common, occurring in about 1 in 100,000 people. The condition has been described throughout ancient history.
Signs and symptoms
The most common manifestation of lymphedema is soft tissue swelling, edema. As the disorder progresses, worsening edema and skin changes including discoloration, verrucous (wart-like) hyperplasia, hyperkeratosis, papillomatosis, dermal thickening and ulcers may be seen. Additionally, there is increased risk of infection of the skin, known as cellulitis.
When the lymphatic impairment becomes so great that the lymph fluid exceeds the lymphatic system's ability to transport it, an abnormal amount of protein-rich fluid collects in the tissues. Left untreated, this stagnant, protein-rich fluid causes tissue channels to increase in size and number, reducing oxygen availability. This interferes with wound healing and provides a rich culture medium for bacterial growth that can result in infections, cellulitis, lymphangitis, lymphadenitis and, in severe cases, skin ulcers. It is vital for lymphedema patients to be aware of the symptoms of infection and to seek immediate treatment, since recurrent infections or cellulitis, in addition to their inherent danger, further damage the lymphatic system and set up a vicious circle.
In rare cases, lymphedema can lead to a form of cancer called lymphangiosarcoma, although the mechanism of carcinogenesis is not understood. Lymphedema-associated lymphangiosarcoma is called Stewart-Treves syndrome. Lymphangiosarcoma most frequently occurs in cases of long-standing lymphedema. The incidence of angiosarcoma is estimated to be 0.45% in patients living 5 years after radical mastectomy. Lymphedema is also associated with a low grade form of cancer called retiform hemangioendothelioma (a low grade angiosarcoma).
Lymphedema may be inherited (primary) or caused by injury to the lymphatic vessels (secondary).
Lymph node damage
It is most frequently seen after lymph node dissection, surgery and/or radiation therapy, in which damage to the lymphatic system is caused during the treatment of cancer, most notably breast cancer. In many patients with cancer, this condition does not develop until months or even years after therapy has concluded. Lymphedema may also be associated with accidents or certain diseases or problems that may inhibit the lymphatic system from functioning properly. In tropical areas of the world, a common cause of secondary lymphedema is filariasis, a parasitic infection. It can also be caused by damage to the lymphatic system from infections such as cellulitis.
Primary lymphedema may be congenital or arise sporadically. Multiple syndromes are associated with primary lymphedema, including Turner syndrome, Milroy's disease, and Klippel-Trenaunay-Weber syndrome. It is generally thought to occur as a result of absent or malformed lymph nodes and/or lymphatic channels. Lymphedema may be present at birth, develop at the onset of puberty (praecox), or not become apparent for many years into adulthood (tarda). In men, lower-limb primary lymphedema is most common, occurring in one or both legs. Some cases of lymphedema may be associated with other vascular abnormalities.
Secondary lymphedema affects both men and women. In women, it is most prevalent in the upper limbs after breast cancer surgery, in particular after axillary lymph node dissection, occurring in the arm on the side of the body in which the surgery is performed. Breast and trunk lymphedema can also occur but go unrecognised as there is swelling in the area after surgery, and its symptoms (peau d'orange and/or an inverted nipple) can be confused with post surgery fat necrosis. In Western countries, secondary lymphedema is most commonly due to cancer treatment. Between 38 and 89% of breast cancer patients suffer from lymphedema due to axillary lymph node dissection and/or radiation. Unilateral lymphedema occurs in up to 41% of patients after gynecologic cancer. For men, a 5-66% incidence of lymphedema has been reported in patients treated with incidence depending on whether staging or radical removal of lymph glands was done in addition to radiotherapy.
Head and neck lymphedema can be caused by surgery or radiation therapy for tongue or throat cancer. It may also occur in the lower limbs or groin after surgery for colon, ovarian or uterine cancer, in which removal of lymph nodes or radiation therapy is required. Surgery or treatment for prostate, colon and testicular cancers may result in secondary lymphedema, particularly when lymph nodes have been removed or damaged.
The onset of secondary lymphedema in patients who have had cancer surgery has also been linked to aircraft flight (likely due to decreased cabin pressure or relative immobility). For cancer survivors, therefore, wearing a prescribed and properly fitted compression garment may help decrease swelling during air travel.
Some cases of lower-limb lymphedema have been associated with the use of tamoxifen, due to the blood clots and deep vein thrombosis (DVT) that can be associated with this medication. Resolution of the blood clots or DVT is needed before lymphedema treatment can be initiated.
Infectious causes include lymphatic filariasis.
Hereditary lymphedema is a primary lymphedema – swelling that results from abnormalities in the lymphatic system that are present from birth. Swelling may be present in a single affected limb, several limbs, genitalia, or the face. It is sometimes diagnosed prenatally by a nuchal scan or post-natally by lymphoscintigraphy. The most common form is Meige disease that usually presents at puberty. Another form of hereditary lymphedema is Milroy's disease caused by mutations in the VEGFR3 gene. Hereditary lymphedema is frequently syndromic and is associated with Turner syndrome, lymphedema–distichiasis syndrome, yellow nail syndrome, and Klippel–Trénaunay–Weber syndrome.
One defined genetic cause for hereditary lymphedema is GATA2 deficiency. This deficiency is a grouping of several disorders caused by common defect, viz., familial or sporadic inactivating mutations in one of the two parental GATA2 genes. These autosomal dominant mutations cause a reduction, i.e. a haploinsufficiency, in the cellular levels of the gene's product, GATA2. The GATA2 protein is a transcription factor critical for the embryonic development, maintenance, and functionality of blood-forming, lympathic-forming, and other tissue-forming stem cells. In consequence of these mutations, cellular levels of GATA2 are deficient and individuals develop over time hematological, immunological, lymphatic, and/or other disorders. GATA2 deficiency-induced defects in the lymphatic vessels and valves underlies the development of lymphedema which is primarily located in the lower extremities but may also occur in other places such as the face or testes (i.e. hydrocele). This form of the deficiency, when coupled with sensorineural hearing loss which may also be due to faulty development of the lymphatic system, is sometimes termed the Emberger syndrome.
Primary lymphedema has a quoted incidence of approximately 1-3 births out of every 10,000 births, with a particular female preponderance to male ratio of 3.5:1 In North America, the incidence of primary lymphedema is approximately 1.15 births out of every 100,000 births Compared to secondary lymphedema, primary lymphedema is relatively rare.
Bilateral lower extremity inflammatory lymphedema (BLEIL) is a distinct type of lymphedema occurring in a setting of acute and prolonged standing, such as in new recruits during basic training. The possible underlying mechanisms are thought to be venous congestion and inflammatory vasculitis.
Lymph is formed from the fluid that filters out of the blood circulation and contains proteins, cellular debris, bacteria, etc. The collection of this fluid is carried out by the initial lymph collectors that are blind-ended epithelial-lined vessels with fenestrated openings that allow fluids and particles as large as cells to enter. Once inside the lumen of the lymphatic vessels, the fluid is guided along increasingly larger vessels, first with rudimentary valves to prevent backflow, which later develop into complete valves similar to the venous valve. Once the lymph enters the fully valved lymphatic vessels, it is pumped by a rhythmic peristaltic-like action by smooth muscle cells within the lymphatic vessel walls. This peristaltic action is the primary driving force, moving lymph within its vessel walls. The regulation of the frequency and power of contraction is regulated by the sympathetic nervous system. Lymph movement can be influenced by the pressure of nearby muscle contraction, arterial pulse pressure and the vacuum created in the chest cavity during respiration, but these passive forces contribute only a minor percentage of lymph transport. The fluids collected are pumped into continually larger vessels and through lymph nodes, which remove debris and police the fluid for dangerous microbes. The lymph ends its journey in the thoracic duct or right lymphatic duct, which drain into the blood circulation.
Diagnosis is generally based on signs and symptoms, with testing used to rule out other potential causes. An accurate diagnosis and staging may help with management. A swollen limb can result from different conditions that require different treatments. Diagnosis of lymphedema is currently based on history, physical exam, and limb measurements. Imaging studies such as lymphoscintigraphy and indocyanine green lymphography are only required when surgery is being considered. However, the ideal method for lymphedema staging to guide the most appropriate treatment is controversial because of several different proposed protocols. Lymphedema can occur in both the upper and lower extremities, and in some cases, the head and neck. Assessment of the extremities first begins with a visual inspection. Color, presence of hair, visible veins, size and any sores or ulcerations are noted. Lack of hair may indicate an arterial circulation problem. Given swelling, the extremities' circumference is measured for reference as time continues. In early stages of lymphedema, elevating the limb may reduce or eliminate the swelling. Palpation of the wrist or ankle can determine the degree of swelling; assessment includes a check of the pulses. The axillary or inguinal nodes may be enlarged due to the swelling. Enlargement of the nodes lasting more than three weeks may indicate infection or other illnesses such as sequela from breast cancer surgery requiring further medical attention.
Diagnosis or early detection of lymphedema is difficult. The first signs may be subjective observations such as a feeling of heaviness in the affected extremity. These may be symptomatic of early stage of lymphedema where accumulation of lymph is mild and not detectable by changes in volume or circumference. As lymphedema progresses, definitive diagnosis is commonly based upon an objective measurement of differences between the affected or at-risk limb at the opposite unaffected limb, e.g. in volume or circumference. No generally accepted criterion is definitively diagnostic, although a volume difference of 200 ml between limbs or a 4-cm difference (at a single measurement site or set intervals along the limb) is often used. Bioimpedance measurement (which measures the amount of fluid in a limb) offers greater sensitivity than existing methods.
Chronic venous stasis changes can mimic early lymphedema, but the changes in venous stasis are more often bilateral and symmetric. Lipedema can also mimic lymphedema, however lipedema characteristically spares the feet beginning abruptly at the medial malleoli (ankle level). As a part of the initial work-up before diagnosing lymphedema, it may be necessary to exclude other potential causes of lower extremity swelling such as kidney failure, hypoalbuminemia, congestive heart-failure, protein-losing nephropathy, pulmonary hypertension, obesity, pregnancy and drug-induced edema.
According to the Fifth WHO Expert Committee on Filariasis the most common method of classification of lymphedema is as follows: (The same classification method can be used for both primary and secondary lymphedema) The International Society of Lymphology (ISL) Staging System is based solely on subjective symptoms, making it prone to substantial observer bias. Imaging modalities have been suggested as useful adjuncts to the ISL staging to clarify the diagnosis. The lymphedema expert Dr. Ming-Huei Cheng developed a Cheng's Lymphedema Grading tool to assess the severity of extremity lymphedema based on objective limb measurements and providing appropriate options for management.
- Grade 1: Spontaneously reversible on elevation. Mostly pitting edema.
- Grade 2: Non-spontaneously reversible on elevation. Mostly non-pitting edema.
- Grade 3: Gross increase in volume and circumference of Grade 2 lymphedema, with eight stages of severity given below based on clinical assessments.
As described by the Fifth WHO Expert Committee on Filariasis, and endorsed by the American Society of Lymphology., the staging system helps to identify the severity of lymphedema. With the assistance of medical imaging apparatus, such as MRI or CT, staging can be established by the physician, and therapeutic or medical interventions may be applied:
- Stage 0: The lymphatic vessels have sustained some damage that is not yet apparent. Transport capacity is sufficient for the amount of lymph being removed. Lymphedema is not present.
- Stage 1 : Swelling increases during the day and disappears overnight as the patient lies flat in bed. Tissue is still at the pitting stage: when pressed by the fingertips, the affected area indents and reverses with elevation. Usually upon waking in the morning, the limb or affected area is normal or almost normal in size. Treatment is not necessarily required at this point.
- Stage 2: Swelling is not reversible overnight, and does not disappear without proper management. The tissue now has a spongy consistency and is considered non-pitting: when pressed by the fingertips, the affected area bounces back without indentation. Fibrosis found in Stage 2 lymphedema marks the beginning of the hardening of the limbs and increasing size.
- Stage 3: Swelling is irreversible and usually the limb(s) or affected area become increasingly large. The tissue is hard (fibrotic) and unresponsive; some patients consider undergoing reconstructive surgery, called "debulking". This remains controversial, however, since the risks may outweigh the benefits and the further damage done to the lymphatic system may in fact make the lymphedema worse.
- Stage 4: The size and circumference of the affected limb(s) become noticeably large. Bumps, lumps, or protusions (also called knobs) on the skin begin to appear.
- Stage 5: The affected limb(s) become grossly large; one or more deep skin folds is prevalent among patients in this stage.
- Stage 6: Knobs of small elongated or small rounded sizes cluster together, giving mossy-like shapes on the limb. Mobility of the patient becomes increasingly difficult.
- Stage 7: The person becomes handicapped, and is unable to independently perform daily routine activities such as walking, bathing and cooking. Assistance from the family and health care system is needed.
Lymphedema can also be categorized by its severity (usually referenced to a healthy extremity):
- Grade 1 (mild edema): Involves the distal parts such as a forearm and hand or a lower leg and foot. The difference in circumference is less than 4 cm and other tissue changes are not yet present.
- Grade 2 (moderate edema): Involves an entire limb or corresponding quadrant of the trunk. Difference in circumference is 4–6 cm. Tissue changes, such as pitting, are apparent. The patient may experience erysipelas.
- Grade 3a (severe edema): Lymphedema is present in one limb and its associated trunk quadrant. Circumferential difference is greater than 6 centimeters. Significant skin alterations, such as cornification or keratosis, cysts and/or fistulae, are present. Additionally, the patient may experience repeated attacks of erysipelas.
- Grade 3b (massive edema): The same symptoms as grade 3a, except that two or more extremities are affected.
- Grade 4 (gigantic edema): In this stage of lymphedema, the affected extremities are huge, due to almost complete blockage of the lymph channels.
Lymphedema should not be confused with edema arising from venous insufficiency, which is caused by compromise of the venous drainage rather than lymphatic drainage. However, untreated venous insufficiency can progress into a combined venous/lymphatic disorder.
While there is no cure, treatment may improve outcomes. This commonly include compression therapy, good skin care, exercise, and manual lymphatic drainage (MLD), which together is known as combined decongestive therapy. MLD is most effective in mild to moderate disease. In breast cancer-related lymphedema, MLD is safe and may offer added benefit to compression bandages for reducing swelling. Most people with lymphedema can be medically managed with conservative treatment. Diuretics are not useful. Surgery is generally only used in those who are not improved with other measures.
Once a person is diagnosed with lymphedema, compression becomes imperative in the management of the condition. Garments are often intended to be worn all day, but may be taken off for sleeping unless otherwise prescribed. Elastic compression garments are worn on the affected limb following complete decongestive therapy to maintain edema reduction. Inelastic garments provide containment and reduction. Available styles, options, and prices vary widely. A professional garment fitter or certified lymphedema therapist can help determine the best option for the patient.
Compression bandaging, also called wrapping, is the application of layers of padding and short-stretch bandages to the involved areas. Short-stretch bandages are preferred over long-stretch bandages (such as those normally used to treat sprains), as the long-stretch bandages cannot produce the proper therapeutic tension necessary to safely reduce lymphedema and may in fact end up producing a tourniquet effect. During activity, whether exercise or daily activities, the short-stretch bandages enhance the pumping action of the lymph vessels by providing increased resistance. This encourages lymphatic flow and helps to soften fluid-swollen areas.
Intermittent pneumatic compression therapy
Intermittent pneumatic compression therapy (IPC) utilizes a multi-chambered pneumatic sleeve with overlapping cells to promote movement of lymph fluid. Pump therapy should be used in addition to other treatments such as compression bandaging and manual lymph drainage. Pump therapy has been used a lot in the past to help with controlling lymphedema. In some cases, pump therapy helps soften fibrotic tissue and therefore potentially enable more efficient lymphatic drainage. However, reports link pump therapy to increased incidence of edema proximal to the affected limb, such as genital edema arising after pump therapy in the lower limb. IPC should be used in combination with complete decongestive therapy.
In those with lymphedema or at risk of developing lymphedema, following breast cancer treatment, resistance training did not increase swelling and decreases in some, in addition to other potential beneficial effects on cardiovascular health. Moreover, resistance training and other forms of exercise were not associated with an increased risk of developing lymphedema in people who previously received breast cancer-related treatment. Compression garments should be worn during exercise (with the possible exception of swimming).
While a number of surgical methods have been tried, many have been shown not to be effective. In very severe disease two methods may be tried: removal of excess tissue and reconstruction of the lymphatic tissue.
Suction assisted lipectomy (SAL), also known as liposuction for lymphedema, may help improve chronic non pitting edema if present. The procedure removes fat and protein and is done along with continued compression therapy.
Vascularized lymph node transfers (VLNT) and lymphovenous bypass are supported by tentative evidence as of 2017 but is associated with a number of complications.
According to the US National Cancer Institute, LLLT may be effective in reducing lymphedema in some women. Two cycles of laser treatment were found to be reduce the volume of the affected arm in approximately one-third of people with postmastectomy lymphedema at 3 months post-treatment.
Lymphedema affects approximately 200 million people worldwide.
- Grada AA, Phillips TJ (December 2017). "Lymphedema: Diagnostic workup and management". Journal of the American Academy of Dermatology. 77 (6): 995–1006. doi:10.1016/j.jaad.2017.03.021. PMID 29132859.
- Sleigh, BC; Manna, B (July 2020). "Lymphedema". PMID 30725924. Cite journal requires
- "Lymphedema (PDQ®)–Health Professional Version - National Cancer Institute". www.cancer.gov. 30 June 2008. Retrieved 20 February 2021.
- Grada AA, Phillips TJ (December 2017). "Lymphedema: Pathophysiology and clinical manifestations". Journal of the American Academy of Dermatology. 77 (6): 1009–1020. doi:10.1016/j.jaad.2017.03.022. PMID 29132848.
- Tyring, Steven K.; Lupi, Omar; Hengge, Ulrich R. (2016). Tropical Dermatology E-Book. Elsevier Health Sciences. p. 57. ISBN 978-0-323-33914-8.
- Martin MB, Kon ND, Kawamoto EH, Myers RT, Sterchi JM (October 1984). "Postmastectomy angiosarcoma". The American Surgeon. 50 (10): 541–5. PMID 6541442.
- Chopra S, Ors F, Bergin D (December 2007). "MRI of angiosarcoma associated with chronic lymphoedema: Stewart Treves syndrome". The British Journal of Radiology. 80 (960): e310-3. doi:10.1259/bjr/19441948. PMID 18065640.
- Requena L, Sangueza OP (February 1998). "Cutaneous vascular proliferations. Part III. Malignant neoplasms, other cutaneous neoplasms with significant vascular component, and disorders erroneously considered as vascular neoplasms". Journal of the American Academy of Dermatology. 38 (2 Pt 1): 143–75, quiz 176–8. doi:10.1016/S0190-9622(98)70237-3. PMID 9486670.
- Publishing, Licorn (2009-10-28). "Body image and quality of life in secondary lymphedema of the upper limb". Servier - Phlebolymphology. Archived from the original on 2019-09-03. Retrieved 2019-09-03.
- "Oncology Fact Sheet" (PDF). aota.org. Retrieved 2019-09-03.
- Jeannie Burt; Gwen White (1 January 2005). Lymphedema: A Breast Cancer Patient's Guide to Prevention and Healing. Hunter House. pp. 9. ISBN 978-0-89793-458-9.
- Choices, NHS. "IPS retired" (PDF). nhs.uk. Retrieved 9 May 2018.
- Brorson H, Ohlin K, Olsson G, Svensson B, Svensson H (June 2008). "Controlled compression and liposuction treatment for lower extremity lymphedema". Lymphology. 41 (2): 52–63. PMID 18720912.
- Kissin MW, Querci della Rovere G, Easton D, Westbury G (July 1986). "Risk of lymphoedema following the treatment of breast cancer". The British Journal of Surgery. 73 (7): 580–4. doi:10.1002/bjs.1800730723. PMID 3730795.
- Segerström K, Bjerle P, Graffman S, Nyström A (1992). "Factors that influence the incidence of brachial oedema after treatment of breast cancer". Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery. 26 (2): 223–7. doi:10.3109/02844319209016016. PMID 1411352.
- Werngren-Elgström M, Lidman D (December 1994). "Lymphoedema of the lower extremities after surgery and radiotherapy for cancer of the cervix". Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery. 28 (4): 289–93. doi:10.3109/02844319409022014. PMID 7899840.
- Pilepich MV, Asbell SO, Mulholland GS, Pajak T (1984). "Surgical staging in carcinoma of the prostate: the RTOG experience. Radiation Therapy Oncology Group". The Prostate. 5 (5): 471–6. doi:10.1002/pros.2990050502. PMID 6483687.
- Pilepich MV, Krall J, George FW, Asbell SO, Plenk HD, Johnson RJ, et al. (October 1984). "Treatment-related morbidity in phase III RTOG studies of extended-field irradiation for carcinoma of the prostate". International Journal of Radiation Oncology, Biology, Physics. 10 (10): 1861–7. doi:10.1016/0360-3016(84)90263-3. PMID 6386761.
- Liem TK, Moneta GL (2010). "Chapter 24. Venous and Lymphatic Disease". In Brunicardi FC, Andersen DK, Billiar TR, Dunn DL, Hunter JG, Matthews JB, Pollock RE (eds.). Schwartz's Principles of Surgery (9th ed.). New York, NY: The McGraw-Hill Companies.[permanent dead link]
- Burkhart CN, Adigun C, Burton CS (2012). "Chapter 174. Cutaneous Changes in Peripheral Venous and Lymphatic Insufficiency". In Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K (eds.). Fitzpatrick's Dermatology in General Medicine (8 ed.). New York, NY: The McGraw-Hill Companies.[permanent dead link]
- Crispino JD, Horwitz MS (April 2017). "GATA factor mutations in hematologic disease". Blood. 129 (15): 2103–2110. doi:10.1182/blood-2016-09-687889. PMC 5391620. PMID 28179280.
- Hirabayashi S, Wlodarski MW, Kozyra E, Niemeyer CM (August 2017). "Heterogeneity of GATA2-related myeloid neoplasms". International Journal of Hematology. 106 (2): 175–182. doi:10.1007/s12185-017-2285-2. PMID 28643018.
- Kurland LT, Molgaard CA (October 1981). "The patient record in epidemiology". Scientific American. 245 (4): 54–63. Bibcode:1981SciAm.245d..54K. doi:10.1038/scientificamerican1081-54. PMID 7027437.
- Fajardo, Kevin A.; Keller, Patrick; Kobayashi, Todd; Hivnor, Chad M.; Webber, Bryant J.; Federinko, Susan P.; Tchandja, Juste (1 April 2015). "Bilateral Lower Extremity Inflammatory Lymphedema in Air Force Basic Trainees: Clinical and Epidemiologic Study of a New Disease Entity". JAMA Dermatology. 151 (4): 395. doi:10.1001/jamadermatol.2014.3794.
- McCann, Shannan E.; Dalton, Scott R.; Kobayashi, Todd T. (May 2017). "Histopathology of bilateral lower extremity inflammatory lymphedema in military basic trainees: A leukocytoclastic vasculitis of the deep vascular plexus: MCCANN et al". Journal of Cutaneous Pathology. 44 (5): 500–503. doi:10.1111/cup.12918.
- Burnand KM, Glass DM, Mortimer PS, Peters AM (January 2012). "Lymphatic dysfunction in the apparently clinically normal contralateral limbs of patients with unilateral lower limb swelling". Clinical Nuclear Medicine. 37 (1): 9–13. doi:10.1097/RLU.0b013e31823931f5. PMID 22157021.
- Tiwari A, Cheng KS, Button M, Myint F, Hamilton G (February 2003). "Differential diagnosis, investigation, and current treatment of lower limb lymphedema". Archives of Surgery. 138 (2): 152–61. doi:10.1001/archsurg.138.2.152. PMID 12578410.
- Jarvis, C. (2004). Physical Examination and Health Assessment (5th ed.). Saunders Elsevier. pp. 530–553. ISBN 978-1-4160-5188-6.
- Ward LC (2006). "Bioelectrical impedance analysis: proven utility in lymphedema risk assessment and therapeutic monitoring". Lymphatic Research and Biology. 4 (1): 51–6. doi:10.1089/lrb.2006.4.51. PMID 16569209.
- "Treatment and Prevention of Problems Associated with Lymphatic Filariasis" (PDF). World Health Organization. Archived (PDF) from the original on 2012-04-18. Retrieved 2014-05-16.
- "Lymphatic filariasis: the disease and its control. Fifth report of the WHO Expert Committee on Filariasis". World Health Organization Technical Report Series. 821: 1–71. 1992. PMID 1441569.
- International Society of Lymphology (March 2013). "The diagnosis and treatment of peripheral lymphedema: 2013 Consensus Document of the International Society of Lymphology". Lymphology. 46 (1): 1–11. PMID 23930436.
- Patel KM, Lin CY, Cheng MH (July 2015). "A Prospective Evaluation of Lymphedema-Specific Quality-of-Life Outcomes Following Vascularized Lymph Node Transfer". Annals of Surgical Oncology. 22 (7): 2424–30. doi:10.1245/s10434-014-4276-3. PMID 25515196.
- Cheng M, Chang DW, Patel KM (13 July 2015). Principles and Practice of Lymphedema Surgery. Elsevier Health Sciences. ISBN 978-0-323-29897-1.
- Principles and Practice of Lymphedema Surgery. Cheng MH, Chang DW, Patel KM (Editors). Elsevier Inc, Oxford, United Kingdom. ISBN 978-0-323-29897-1. July 2015.
- Tretbar LL, Morgan CL, Lee B, Simonian SJ, Blondeau B (6 May 2010). Lymphedema: Diagnosis and Treatment. Springer Science & Business Media. ISBN 978-1-84628-793-0.[page needed]
- Lee TS, Morris CM, Czerniec SA, Mangion AJ (February 2018). "Does Lymphedema Severity Affect Quality of Life? Simple Question. Challenging Answers". Lymphatic Research and Biology. 16 (1): 85–91. doi:10.1089/lrb.2016.0049. PMID 28453410.
- Ezzo J, Manheimer E, McNeely ML, Howell DM, Weiss R, Johansson KI, et al. (May 2015). "Manual lymphatic drainage for lymphedema following breast cancer treatment". The Cochrane Database of Systematic Reviews (5): CD003475. doi:10.1002/14651858.CD003475.pub2. PMC 4966288. PMID 25994425.
- Koul R, Dufan T, Russell C, Guenther W, Nugent Z, Sun X, Cooke AL (March 2007). "Efficacy of complete decongestive therapy and manual lymphatic drainage on treatment-related lymphedema in breast cancer". International Journal of Radiation Oncology, Biology, Physics. 67 (3): 841–6. doi:10.1016/j.ijrobp.2006.09.024. PMID 17175115.
- Cheville AL, McGarvey CL, Petrek JA, Russo SA, Taylor ME, Thiadens SR (July 2003). "Lymphedema management". Seminars in Radiation Oncology. 13 (3): 290–301. doi:10.1016/S1053-4296(03)00035-3. PMID 12903017.
- Boris M, Weindorf S, Lasinski BB (March 1998). "The risk of genital edema after external pump compression for lower limb lymphedema". Lymphology. 31 (1): 15–20. PMID 9561507.
- Szuba A, Achalu R, Rockson SG (December 2002). "Decongestive lymphatic therapy for patients with breast carcinoma-associated lymphedema. A randomized, prospective study of a role for adjunctive intermittent pneumatic compression". Cancer. 95 (11): 2260–7. doi:10.1002/cncr.10976. PMID 12436430.
- Furmaniak, Anna C.; Menig, Matthias; Markes, Martina H. (21 September 2016). "Exercise for women receiving adjuvant therapy for breast cancer". The Cochrane Database of Systematic Reviews. 9: CD005001. doi:10.1002/14651858.CD005001.pub3. ISSN 1469-493X. PMC 6457768. PMID 27650122.
- Schmitz KH, Ahmed RL, Troxel A, Cheville A, Smith R, Lewis-Grant L, et al. (August 2009). "Weight lifting in women with breast-cancer-related lymphedema". The New England Journal of Medicine. 361 (7): 664–73. doi:10.1056/NEJMoa0810118. PMID 19675330.
- "Position Paper: Exercise | National Lymphedema Network". Lymphnet.org. Archived from the original on 2014-05-08. Retrieved 2014-05-16.
- Granzow JW, Soderberg JM, Kaji AH, Dauphine C (April 2014). "Review of current surgical treatments for lymphedema". Annals of Surgical Oncology. 21 (4): 1195–201. doi:10.1245/s10434-014-3518-8. PMID 24558061.
- dotmed.com December 27, 2006 Archived January 7, 2010, at the Wayback Machine Low Level Laser FDA Cleared for the Treatment of Lymphedema. (accessed 9 November 09)
- National Cancer Institute: Low-level laser therapy Archived 2009-09-24 at the Wayback Machine accessed 9 November 09
- Carati CJ, Anderson SN, Gannon BJ, Piller NB (September 2003). "Treatment of postmastectomy lymphedema with low-level laser therapy: a double blind, placebo-controlled trial". Cancer. 98 (6): 1114–22. doi:10.1002/cncr.11641. PMID 12973834.